These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 18484677

  • 1. Familial chronic myeloproliferative disorders: the state of the art.
    Rumi E.
    Hematol Oncol; 2008 Sep; 26(3):131-8. PubMed ID: 18484677
    [Abstract] [Full Text] [Related]

  • 2. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 3. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J.
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [Abstract] [Full Text] [Related]

  • 4. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 5. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 6. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 7. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 8. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 9. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.
    Ann Hematol; 2007 Apr 20; 86(4):245-53. PubMed ID: 17262192
    [Abstract] [Full Text] [Related]

  • 10. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O, Levine RL.
    Leukemia; 2008 Oct 20; 22(10):1813-7. PubMed ID: 18754026
    [Abstract] [Full Text] [Related]

  • 11. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, Arcaini L, Pascutto C, Castello A, Cazzola M, Magrini U, Lazzarino M.
    Br J Haematol; 2008 Jan 20; 140(2):162-8. PubMed ID: 18028479
    [Abstract] [Full Text] [Related]

  • 12. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb 20; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 13. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2017 Jan 20; 92(1):94-108. PubMed ID: 27991718
    [Abstract] [Full Text] [Related]

  • 14. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.
    N Engl J Med; 2005 Apr 28; 352(17):1779-90. PubMed ID: 15858187
    [Abstract] [Full Text] [Related]

  • 15. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.
    Plo I, Vainchenker W.
    Clin Lymphoma Myeloma; 2009 Apr 28; 9 Suppl 3():S329-39. PubMed ID: 19778861
    [Abstract] [Full Text] [Related]

  • 16. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.
    Orv Hetil; 2006 Nov 12; 147(45):2175-9. PubMed ID: 17402211
    [Abstract] [Full Text] [Related]

  • 17. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
    Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR.
    Exp Hematol; 2007 Nov 12; 35(11):1641-6. PubMed ID: 17920755
    [Abstract] [Full Text] [Related]

  • 18. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2015 Feb 12; 90(2):162-73. PubMed ID: 25611051
    [Abstract] [Full Text] [Related]

  • 19. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J, Fijnheer R, Walsh IB, Hermans MH.
    Hematol Oncol; 2006 Dec 12; 24(4):227-33. PubMed ID: 17006961
    [Abstract] [Full Text] [Related]

  • 20. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM, Bagg A.
    Int J Lab Hematol; 2015 May 12; 37 Suppl 1():61-71. PubMed ID: 25976962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.